Scilex Holding Company logo

Scilex Holding Company(SCLX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.43
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SCLX

11/13/2026: SCLX (1-star) is currently NOT-A-BUY. Pass it for now.

Scilex Holding Company is a commercial-stage biopharmaceutical firm focused on developing and marketing non-opioid treatments for chronic and acute pain. The company's main strength lies in its diversified, FDA-approved portfolio, including products like ZTlido and Elyxyb, which target large markets seeking alternatives to addictive pain management. Its primary investment story rests on the successful commercial scaling and broader physician adoption of these non-narcotic therapies. However, the company faces notable risks, including high operational cash burn, intense competition from generic alternatives, and potential financing needs. This stock is best suited for growth-oriented investors with a high risk tolerance, who should closely monitor revenue growth and payer reimbursement developments.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers growth potential through product commercialization but carries high execution risk.
Momentum investorMixed fitMomentum fit is conditional on positive price breakouts and institutional interest.
Value investorWeak fitThe company is not currently valued based on traditional earnings or dividend multiples.
Dividend investorWeak fitScilex does not pay a dividend and focuses capital on growth/operations.
Low-risk investorWeak fitSmall-cap biotech stocks exhibit high volatility and business risk unsuitable for low-risk profiles.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock's small-cap status leads to frequent and significant price swings.
Valuation riskHighValuation is often tied to speculative growth rather than established earnings.
Competition risk (Pharma incumbents)HighEstablished pharmaceutical companies can outcompete via larger sales forces and lower prices.
Business qualityMediumThe company is still proving its commercial model and long-term sustainability.
Dividend incomeLow / noneIncome generation is not part of the current business model.
Execution riskHighSuccess relies heavily on meeting complex commercial and regulatory milestones.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 10.06M USD
Price to earnings Ratio -
1Y Target Price 490
Price to earnings Ratio -
1Y Target Price 490
Volume (30-day avg) 44.3K shares
Beta 1.93
52 Weeks Range 1.40 - 16.81
Updated Date 11/14/2026
52 Weeks Range 1.40 - 16.81
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -49.7

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - General

BUY participation
77.8%
Active BUY / eligible
7 / 9
30-Day BUY Count Change
+4

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 11.46%
Avg. Invested days 17
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 2.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SCLX receives a 3-star rating based on the available scored pillars. The rating is constrained by soft company fundamentals, and weak price momentum.

Company Fundamentals

★★★★★
SCLX has soft overall fundamentals (2 stars), with soft financial health, weak growth momentum, and solid ownership. In FY2025 versus FY2024, solid cash generation (FCF margin 12.2%) is partially offset by negative earnings growth (-392.7%), negative revenue growth (-46.5%), weak profitability (net margin -1185.8%).

Financial Health Rating

★★★★★
SCLX's financial health is soft, with the relatively strongest area being moderate cash strength, including free-cash-flow generation (12.2% of revenue). Operating efficiency is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
SCLX's growth profile is soft, with the least-weak measure being revenue growth at -46.5% FY2025 versus FY2024. By comparison, while earnings growth (-392.7%, negative) and free-cash-flow growth (-80.4%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 8.7% and approximately 80.9% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 11.99% supports management-shareholder alignment.

Top 5 Institutional Investors

Vanguard Capital Management, LLC 4.28%
BlackRock Inc 1.56%
Vanguard Fiduciary Trust Co 0.65%
Jacobs Levy Equity Management, Inc. 0.59%
State Street Corp 0.50%

Unit Economics (Per $1K Revenue)

★★★★★
SCLX generates approximately $497 of gross profit, $-9,001 of operating income, and $122 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins and weak cash conversion support a 3-star rating, while capital efficiency is strong.

Economic Dimensions

★★★★★
Effective Tax Rate: 4.09%

Quantitative Style Profile

★★★★★
SCLX has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Commercialized PharmaceuticalsRevenue generated from the sale of ZTlido, Elyxyb, and Gloperba.The company makes money by selling brand-name prescription pain relief drugs to pharmacies and healthcare providers.

Valuation

Trailing PE -
Forward PE 5.58
Enterprise Value 107.20M
Price to Sales(TTM) 0.32
Enterprise Value 107.20M
Price to Sales(TTM) 0.32
Enterprise Value to Revenue 3.39
Enterprise Value to EBITDA -2.64
Shares Outstanding 7.03M
Shares Floating 5.69M
Shares Outstanding 7.03M
Shares Floating 5.69M
Percent Insiders 11.99
Percent Institutions 8.73

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.